Abstract

The paper investigates the outcome of premature newborns with respiratory distress syndrome (RDS) who received surfactant treatment from 2020 to 2022. RDS is a respiratory condition that affects neonates, particularly those born prematurely, due to surfactant deficiency. The lagging growth of the lungs and the collapse of the air sacs contribute to the condition. An exploratory study was designed in different hospitals in Thi-Qar, where 90 cases were collected and distributed into two groups: patients, 50 cases, and control, 50 cases of newborn babies. Between the two groups the results found in this study are the condition results in reduced blood oxygen saturation and respiratory insufficiency. Length of (PICU) stay after acute respiratory distress syndrome (PARDS) of Group patients 14.62±2.17, Group control 13.28±0.74 and mechanical ventilation (conventional/high frequency) of group patients 52.313 ± 3.61, control 31.82 ± 4.735 and about Local Complications we found in Group patients at 26 (65%), control group at 9 (18%). We conclude from this study that PS contributed to reducing the death rate of patients’ Iraqi children through ameliorate pulmonary oxygenation in the acute phase of moderate or severe PARDS